A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
NCT07107373
·
clinicaltrials.gov ↗
ACTIVE_NOT_RECRUITING
Status
150
Enrollment
INDUSTRY
Sponsor class
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
DRUG:
Mavacamten
Sponsor
Bristol-Myers Squibb